Scientists discovered a class of potent antibodies that cross‑neutralize Marburg virus and the related Ravn virus, according to a report in npj Viruses. The antibodies show broad neutralizing activity in vitro and provide a candidate set for therapeutic development or passive immunization strategies against filovirus outbreaks. The work identifies specific epitopes that enable cross‑reactivity and supports accelerated preclinical development of antibody‑based countermeasures. Given Marburg’s high case‑fatality rate, these antibodies could form the basis of rapid response therapeutics or adjuncts to vaccine campaigns in outbreak settings.